Literature DB >> 3044996

Use of lymphokines in treatment of experimental intra-abdominal abscess caused by Bacteroides fragilis.

S V Gollapudi1, A Gupta, H Thadepalli, A Perez.   

Abstract

The role of cell-free soluble factors (lymphokines) derived from mitogen-activated splenic cells of mice previously immunized against Bacteroides fragilis was evaluated in the treatment of B. fragilis intra-abdominal abscess (IAA). Neither clindamycin nor lymphokines alone were effective against an established B. fragilis IAA, but the combination of clindamycin and lymphokines decreased the abscess size and bacterial counts in the majority of animals. This suggests that the synergy of lymphokines with clindamycin effects cure of IAA caused by B. fragilis and that lymphokines might have an application as adjuncts to conventional antimicrobial therapy in this setting.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044996      PMCID: PMC259574          DOI: 10.1128/iai.56.9.2369-2372.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  The enhancing effect of mitogens on the in vivo immune response of rabbits.

Authors:  C G Romball; W O Weigle
Journal:  J Immunol       Date:  1975-08       Impact factor: 5.422

2.  Abdominal trauma, anaerobes, and antibiotics.

Authors:  H Thadepalli; S L Gorbach; P W Broido; J Norsen; L Nyhus
Journal:  Surg Gynecol Obstet       Date:  1973-08

3.  Anaerobic infections. 1.

Authors:  S L Gorbach; J G Bartlett
Journal:  N Engl J Med       Date:  1974-05-23       Impact factor: 91.245

4.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

5.  A novel mitogen released by lipid A-stimulated bone marrow cells.

Authors:  S V Gollapudi; M Kern
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

6.  Evidence for T cell-dependent immunity to Bacteroides fragilis in an intraabdominal abscess model.

Authors:  A B Onderdonk; R B Markham; D F Zaleznik; R L Cisneros; D L Kasper
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

7.  Susceptibility of anaerobic bacteria in vitro to 23 antimicrobial agents.

Authors:  V T Bach; H Thadepalli
Journal:  Chemotherapy       Date:  1980       Impact factor: 2.544

8.  Enhancement of reaginic antibody formation in the mouse by concanavalin A.

Authors:  V S Gollapudi; L S Kind
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

9.  A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection.

Authors:  J W van der Meer; M Barza; S M Wolff; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

10.  Cellular immunity to Bacteroides fragilis capsular polysaccharide.

Authors:  M E Shapiro; A B Onderdonk; D L Kasper; R W Finberg
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  4 in total

1.  Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.

Authors:  H Thadepalli; S K Chuah; U Reddy; N Hanna; R Clark; R J Polzer; S Gollapudi
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

2.  In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis.

Authors:  S V Gollapudi; S K Chuah; T Harvey; H D Thadepalli; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

3.  Efficacy of telithromycin (HMR 3647) against enterococci in a mouse peritonitis model.

Authors:  K V Singh; K K Zscheck; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

4.  Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies.

Authors:  Nader S Abutaleb; Mohamed N Seleem
Journal:  Int J Antimicrob Agents       Date:  2019-10-26       Impact factor: 5.283

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.